Copyright: © 2000 Elsevier Ltd. Published by Elsevier Ltd. The deregulated tyrosine kinase activity of the BCR-ABL fusion protein has been established as the ...

Integrative Analyses Reveal the Functional and Genetic Associations of Gene Fusions in Cancer. submitted; 2009. Wu SQ, Voelkerding KV, Sabatini L, Chen XR, Huang J, Meisner LF. Extensive amplification ...

Imatinib is widely used in the treatment of chronic myeloid leukemia (CML), a disorder characterized by the presence of the BCR-ABL fusion gene; however, the therapeutic options for patients with ...

ELVN-001 targets the BCR-ABL gene fusion, addressing resistance issues seen with other TKIs, including the T315I mutation. Financially, Enliven has a market cap of $1.9bn and a cash runway of 7 ...

Imatinib, a drug that targets the BCR-ABL tyrosine kinase, has proved remarkably effective in restoring normal blood formation in people with CML; nevertheless, most individuals in remission have ...

Three months later, a new evaluation of the patient revealed a better cytogenetic response. However, after a year of treatment the results of a FISH analysis showed a positive BCR-ABL fusion gene in ...